Jeffrey L. Stein Ph.D.
Net Worth

Last updated:

What is Jeffrey L. Stein Ph.D. net worth?

The estimated net worth of Dr. Jeffrey L. Stein Ph.D. is at least $9,874,680 as of 7 Jun 2024. He owns shares worth $1,499,380 as insider and has received compensation worth at least $8,375,300 in Cidara Therapeutics, Inc..

What is the salary of Jeffrey L. Stein Ph.D.?

Dr. Jeffrey L. Stein Ph.D. salary is $837,530 per year as Pres, Chief Executive Officer & Executive Director in Cidara Therapeutics, Inc..

How old is Jeffrey L. Stein Ph.D.?

Dr. Jeffrey L. Stein Ph.D. is 70 years old, born in 1955.

What stocks does Jeffrey L. Stein Ph.D. currently own?

As insider, Dr. Jeffrey L. Stein Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Cidara Therapeutics, Inc. (CDTX) Pres, Chief Executive Officer & Executive Director 24,580 $61 $1,499,380

What does Cidara Therapeutics, Inc. do?

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

CDTX logo
CDTX
Cidara Therapeutics, Inc.
$61

Jeffrey L. Stein Ph.D. insider trading

Cidara Therapeutics, Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 8,000 $13.21 $105,680
Purchase
Common Stock 50,000 $0.96 $47,900
Purchase
Common Stock 50,000 $1.04 $51,850
Option
Restricted Stock Unit 20,000 N/A N/A
Option
Common Stock 20,000 N/A N/A
Purchase
Common Stock 50,000 $1.59 $79,550
Purchase
Common Stock 10,000 $1.79 $17,870
Purchase
Common Stock 40,000 $1.72 $68,880
Purchase
Common Stock 50,000 $2 $100,000
Purchase
Common Stock 52,500 N/A N/A
Option
Restricted Stock Unit 10,000 N/A N/A
Option
Restricted Stock Unit 60,000 N/A N/A
Purchase
Common Stock 212,766 $4.7 $1,000,000
Purchase
Common Stock 7,350 $6.79 $49,907
Purchase
Common Stock 15,000 $5.95 $89,205
Purchase
Common Stock 12,900 $7.75 $99,975
Purchase
Common Stock 4,310 $11.51 $49,608
Purchase
Common Stock 1,300 $15.6 $20,280
Purchase
Common Stock 5,400 $14.97 $80,838
Purchase
Common Stock 420 $16 $6,720

Cidara Therapeutics key executives

Cidara Therapeutics, Inc. executives and other stock owners filed with the SEC: